99 related articles for article (PubMed ID: 3761321)
21. Antituberculous activity of norfloxacin mannich bases with isatin derivatives.
Pandeya SN; Sriram D; Yogeeswari P; Ananthan S
Chemotherapy; 2001; 47(4):266-9. PubMed ID: 11399863
[TBL] [Abstract][Full Text] [Related]
22. Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
Edwards R; Kanematsu M; Greenwood D
J Antimicrob Chemother; 1988 Dec; 22(6):885-90. PubMed ID: 3243736
[TBL] [Abstract][Full Text] [Related]
23. Studies on prodrugs. IV. Preparation and characterization of N-(5-substituted 2-oxo-1,3-dioxol-4-yl)methyl norfloxacin.
Sakamoto F; Ikeda S; Kondo H; Tsukamoto G
Chem Pharm Bull (Tokyo); 1985 Nov; 33(11):4870-7. PubMed ID: 3830420
[No Abstract] [Full Text] [Related]
24. Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.
Qadri SM; Johnson S
J Natl Med Assoc; 1989 Apr; 81(4):382-5. PubMed ID: 2738947
[TBL] [Abstract][Full Text] [Related]
25. Amino acid norfloxacin derivatives as prodrugs.
Hribar-Kikelj A; Fercej-Temeljotov D; Zmitek J
Pharmazie; 1993 Jan; 48(1):64-5. PubMed ID: 8460176
[No Abstract] [Full Text] [Related]
26. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Holmes B; Brogden RN; Richards DM
Drugs; 1985 Dec; 30(6):482-513. PubMed ID: 3908074
[TBL] [Abstract][Full Text] [Related]
27. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison.
Chantot JF; Bryskier A
J Antimicrob Chemother; 1985 Oct; 16(4):475-84. PubMed ID: 3864775
[TBL] [Abstract][Full Text] [Related]
28. Antibacterial activity and pharmacokinetics in mice of two new derivatives of norfloxacin.
Balsari A; Dubini F; Stradi R; Riviera L
Chemioterapia; 1987 Jun; 6(2 Suppl):176-8. PubMed ID: 3509384
[No Abstract] [Full Text] [Related]
29. Norfloxacin: a new targeted fluoroquinolone antimicrobial agent.
Wolfson JS; Hooper DC
Ann Intern Med; 1988 Feb; 108(2):238-51. PubMed ID: 3277508
[TBL] [Abstract][Full Text] [Related]
30. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity.
Goldstein EJ
Am J Med; 1987 Jun; 82(6B):3-17. PubMed ID: 3111257
[TBL] [Abstract][Full Text] [Related]
31. Norfloxacin and silver-norfloxacin as topical antimicrobial agents: results of in vitro susceptibility testing against bacteria and Candida sp isolated from burn patients.
Holder IA; Knoll CA; Wesselman J
J Burn Care Rehabil; 1986; 7(6):479-83. PubMed ID: 3429479
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
Debbia E; Schito GC; Nicoletti G; Speciale A
Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
[TBL] [Abstract][Full Text] [Related]
33. Bactericidal and cytotoxic effect of combination of norfloxacin and 5-fluorouracil.
Castelli M; Bertolini A; Baggio G; Aresca P; Bossa R; Galatulas I
Anticancer Res; 1989; 9(1):49-52. PubMed ID: 2705756
[TBL] [Abstract][Full Text] [Related]
34. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
Piccolomini R; Allocati N; Catamo G
Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
[TBL] [Abstract][Full Text] [Related]
35. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
36. Manipulation of the oropharyngeal and intestinal microflora by norfloxacin: microbiological and clinical aspects.
Edlund C; Nord CE
Scand J Infect Dis Suppl; 1988; 56():14-21. PubMed ID: 3074461
[TBL] [Abstract][Full Text] [Related]
37. Diglyceride prodrug strategy for enhancing the bioavailability of norfloxacin.
Dhaneshwar S; Tewari K; Joshi S; Godbole D; Ghosh P
Chem Phys Lipids; 2011 May; 164(4):307-13. PubMed ID: 21477584
[TBL] [Abstract][Full Text] [Related]
38. Novel Glycoconjugate of 8-Fluoro Norfloxacin Derivatives as Gentamicin-resistant Staphylococcus aureus Inhibitors: Synthesis and Molecular Modelling Studies.
Azad CS; Bhunia SS; Krishna A; Shukla PK; Saxena AK
Chem Biol Drug Des; 2015 Oct; 86(4):440-6. PubMed ID: 25546316
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and antibacterial activity of some novel N-substituted piperazinyl-quinolones.
Foroumadi A; Davood A; Mirzaei M; Emami S; Moshafi MH
Boll Chim Farm; 2001; 140(6):411-6. PubMed ID: 11822230
[TBL] [Abstract][Full Text] [Related]
40. 1-Chloropiperazinic derivative (ER 311) of norfloxacin: antibacterial activity in vitro and pharmacokinetic properties in mice.
Dubini F; Balsari A; Stradi R; Riviera L
Chemioterapia; 1987 Jun; 6(2 Suppl):178-80. PubMed ID: 3509385
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
